

# Tetsuya Nakatsura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9056912/publications.pdf>

Version: 2024-02-01

98  
papers

4,956  
citations

109137

35  
h-index

98622

67  
g-index

99  
all docs

99  
docs citations

99  
times ranked

5876  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting. <i>British Journal of Cancer</i> , 2022, 126, 606-614.	2.9	12
2	Development of antigen prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse. <i>Cancer Science</i> , 2022, , .	1.7	4
3	Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. <i>Cancer Science</i> , 2022, , .	1.7	3
4	Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy. <i>Immunological Medicine</i> , 2021, 44, 10-15.	1.4	14
5	Histological characteristics of lung adenocarcinoma with uncommon actionable alterations: special emphasis on <i>MET</i> exon 14 skipping alterations. <i>Histopathology</i> , 2021, 78, 987-999.	1.6	3
6	Tumor-Infiltrating T Cells Concurrently Overexpress CD200R with Immune Checkpoints PD-1, CTLA-4, and TIM-3 in Non-Small-Cell Lung Cancer. <i>Pathobiology</i> , 2021, 88, 218-227.	1.9	2
7	Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer. <i>Genome Biology</i> , 2021, 22, 9.	3.8	58
8	A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy. <i>Nature Communications</i> , 2021, 12, 430.	5.8	111
9	Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 550.	1.7	6
10	Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer. <i>Cancer Immunology Research</i> , 2021, 9, 624-636.	1.6	13
11	Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses. <i>International Journal of Cancer</i> , 2021, 149, 546-560.	2.3	18
12	A Low Tumor Mutational Burden and <i>PTEN</i> Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3714-3724.	3.2	61
13	Immune cell therapy against disseminated melanoma by utilizing induced pluripotent stem cell-derived myeloid cell lines producing interferon-beta or interleukin-15/interleukin-15 receptor alpha. <i>Journal of Dermatological Science</i> , 2021, 102, 133-136.	1.0	3
14	Induced pluripotent stem cell-derived, genetically engineered myeloid cells as unlimited cell source for dendritic cell-related cancer immunotherapy. <i>Journal of Immunology and Regenerative Medicine</i> , 2021, 12, 100042.	0.2	0
15	Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 171-179.	1.8	11
16	Greater extent of blood-tumor TCR repertoire overlap is associated with favorable clinical responses to PD-1 blockade. <i>Cancer Science</i> , 2021, 112, 2993-3004.	1.7	5
17	Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1035-1054.	1.8	17
18	Heat Shock Protein 105 as an Immunotherapeutic Target for Patients With Cervical Cancer. <i>Anticancer Research</i> , 2021, 41, 4741-4751.	0.5	1

#	ARTICLE	IF	CITATIONS
19	Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 564714.	1.3	8
20	Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response. <i>Oncolimmunology</i> , 2020, 9, 1814620.	2.1	13
21	Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells. <i>Cancer Science</i> , 2020, 111, 1478-1490.	1.7	74
22	Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer. <i>Cancer Science</i> , 2020, 111, 23-35.	1.7	25
23	Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. <i>Cancer Science</i> , 2020, 111, 334-342.	1.7	13
24	Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer. <i>Cancer Science</i> , 2020, 111, 2736-2746.	1.7	12
25	Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. <i>Cancer Science</i> , 2020, 111, 2747-2759.	1.7	19
26	Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radical surgery. <i>Oncology Letters</i> , 2020, 19, 2657-2666.	0.8	9
27	First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. , 2019, 7, 195.		32
28	Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial. <i>Cancer Science</i> , 2019, 110, 3049-3060.	1.7	20
29	Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells. <i>Cell Reports</i> , 2019, 29, 162-175.e9.	2.9	26
30	Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes. <i>Cancer Science</i> , 2019, 110, 1842-1852.	1.7	9
31	Next-Generation Cancer Immunotherapy Targeting Glypican-3. <i>Frontiers in Oncology</i> , 2019, 9, 248.	1.3	86
32	Selective elimination of undifferentiated human pluripotent stem cells using pluripotent state-specific immunogenic antigen Glypican-3. <i>Biochemical and Biophysical Research Communications</i> , 2019, 511, 711-717.	1.0	11
33	Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery. <i>Scientific Reports</i> , 2019, 9, 5925.	1.6	6
34	Efficacy of the NCCV Cocktail vaccine for refractory pediatric solid tumors: A phase I clinical trial. <i>Cancer Science</i> , 2019, 110, 3650-3662.	1.7	8
35	bTMB-High Basket trial: A multicenter phase II trial of nivolumab monotherapy in patients with advanced gastrointestinal cancers with high blood tumor mutational burden (bTMB).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS179-TPS179.	0.8	2
36	Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. <i>World Journal of Meta-analysis</i> , 2019, 7, 80-95.	0.1	2

#	ARTICLE	IF	CITATIONS
37	Cancer immunotherapyâ€targeted glypicanâ€3 or neoantigens. <i>Cancer Science</i> , 2018, 109, 531-541.	1.7	40
38	BCRâ€ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells. <i>Cellular and Molecular Immunology</i> , 2018, 15, 15-26.	4.8	5
39	Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors. <i>Oncolmmunology</i> , 2018, 7, e1377872.	2.1	39
40	Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy. <i>Cell Stem Cell</i> , 2018, 23, 850-858.e4.	5.2	110
41	Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification. <i>Scientific Reports</i> , 2018, 8, 13166.	1.6	46
42	Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment. <i>PLoS ONE</i> , 2018, 13, e0191109.	1.1	100
43	Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. <i>Oncolmmunology</i> , 2017, 6, e1346764.	2.1	69
44	Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 37835-37844.	0.8	23
45	Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model. <i>Biochemistry and Biophysics Reports</i> , 2016, 5, 482-491.	0.7	11
46	Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. <i>Oncolmmunology</i> , 2016, 5, e1238542.	2.1	37
47	Hepatocellular carcinoma cell sensitivity to VÎ³9VÎ²2 T lymphocyte-mediated killing is increased by zoledronate. <i>International Journal of Oncology</i> , 2016, 48, 1794-1804.	1.4	13
48	Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. <i>Oncolmmunology</i> , 2016, 5, e1129483.	2.1	125
49	Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice. <i>Biochemical and Biophysical Research Communications</i> , 2016, 469, 138-143.	1.0	23
50	Identification of glypican-3-derived long peptides activating both CD8 <sup>+</sup> and CD4 <sup>+</sup> T cells; prolonged overall survival in cancer patients with Th cell response. <i>Oncolmmunology</i> , 2016, 5, e1062209.	2.1	36
51	A Novel High-Throughput 3D Screening System for EMT Inhibitors: A Pilot Screening Discovered the EMT Inhibitory Activity of CDK2 Inhibitor SU9516. <i>PLoS ONE</i> , 2016, 11, e0162394.	1.1	57
52	Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. <i>International Journal of Oncology</i> , 2015, 46, 28-36.	1.4	69
53	Timeâ€lapse imaging assay using the BioStation CT : Aâ€sensitive drugâ€screening method for threeâ€dimensional cell culture. <i>Cancer Science</i> , 2015, 106, 757-765.	1.7	9
54	A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer. <i>International Journal of Oncology</i> , 2015, 46, 497-504.	1.4	29

#	ARTICLE	IF	CITATIONS
55	Biomarkers for the early diagnosis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 10573.	1.4	377
56	Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. <i>Oncology Reports</i> , 2015, 33, 1837-1843.	1.2	621
57	Glypican 3 Expression in Pediatric Malignant Solid Tumors. <i>European Journal of Pediatric Surgery</i> , 2015, 25, 138-144.	0.7	28
58	Potentiality of immunotherapy against hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 10314.	1.4	32
59	Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2014, 1, 35.	1.8	17
60	Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 338-343.	1.4	27
61	Identification of a novel HLA-A*02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene. <i>Oncology Reports</i> , 2014, 32, 33-39.	1.2	6
62	Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus. <i>Oncology Reports</i> , 2014, 32, 1772-1778.	1.2	18
63	Large-scale expansion of $\beta$ 2 $\mu$ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy. <i>International Journal of Oncology</i> , 2014, 45, 1847-1856.	1.4	8
64	Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer. <i>Oncology Reports</i> , 2014, 31, 1051-1058.	1.2	16
65	Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 639-652.	2.0	37
66	Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein expression. <i>Human Pathology</i> , 2013, 44, 526-533.	1.1	28
67	Peptide intra-tumor injection for cancer immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1234-1236.	1.4	13
68	Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1228-1233.	1.4	30
69	Peptide vaccines for hepatocellular carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 210-212.	1.4	28
70	Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide. <i>International Journal of Oncology</i> , 2013, 43, 1019-1026.	1.4	22
71	Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. <i>International Journal of Oncology</i> , 2013, 42, 831-838.	1.4	15
72	Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. <i>International Journal of Oncology</i> , 2012, 40, 63-70.	1.4	54

#	ARTICLE	IF	CITATIONS
73	Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival. <i>Clinical Cancer Research</i> , 2012, 18, 3686-3696.	3.2	246
74	A glypican-3-derived peptide vaccine against hepatocellular carcinoma. <i>OncoImmunology</i> , 2012, 1, 1448-1450.	2.1	22
75	HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. <i>Cancer Science</i> , 2011, 102, 918-925.	1.7	66
76	Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. <i>Cancer Science</i> , 2011, 102, 1622-1629.	1.7	22
77	Postoperative serum Î±-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. <i>Oncology Reports</i> , 2010, 24, 521-8.	1.2	42
78	Identification of Î²2-microglobulin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis. <i>Oncology Reports</i> , 2010, 23, 1325-30.	1.2	13
79	The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. <i>International Journal of Cancer</i> , 2010, 126, 2153-2163.	2.3	29
80	Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G <sub>1</sub> arrest induction. <i>Cancer Science</i> , 2010, 101, 913-919.	1.7	19
81	Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. <i>International Journal of Oncology</i> , 2009, 34, 649-56.	1.4	58
82	Identification of the H2K <sup>d</sup> -restricted cytotoxic T lymphocyte epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice. <i>Cancer Science</i> , 2009, 100, 132-137.	1.7	8
83	Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. <i>Cancer Science</i> , 2009, 100, 1403-1407.	1.7	222
84	Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis. <i>Oncology Reports</i> , 2009, 22, 149-54.	1.2	8
85	Differential expression of heat shock protein 105 in melanoma and melanocytic naevi. <i>Melanoma Research</i> , 2008, 18, 166-171.	0.6	17
86	HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. <i>International Journal of Oncology</i> , 2008, 32, 985-90.	1.4	21
87	Immunization with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice. <i>Biochemical and Biophysical Research Communications</i> , 2006, 343, 269-278.	1.0	16
88	Embryonic Stem Cell-Derived Dendritic Cells Expressing Glypican-3, a Recently Identified Oncofetal Antigen, Induce Protective Immunity against Highly Metastatic Mouse Melanoma, B16-F10. <i>Cancer Research</i> , 2006, 66, 2414-2422.	0.4	68
89	Synthetic small interfering RNA targeting heat shock protein 105 induces apoptosis of various cancer cells both in vitro and in vivo. <i>Cancer Science</i> , 2006, 97, 623-632.	1.7	53
90	Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 2689-2697.	3.2	161

#	ARTICLE	IF	CITATIONS
91	DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4+ T cells and CD8+ T cells. <i>Cancer Science</i> , 2005, 96, 695-705.	1.7	29
92	Highly Sensitive Detection of Melanoma at an Early Stage Based on the Increased Serum Secreted Protein Acidic and Rich in Cysteine and Glypican-3 Levels. <i>Clinical Cancer Research</i> , 2005, 11, 8079-8088.	3.2	63
93	Usefulness of the Novel Oncofetal Antigen Glypican-3 for Diagnosis of Hepatocellular Carcinoma and Melanoma. <i>BioDrugs</i> , 2005, 19, 71-77.	2.2	59
94	Identification of Glypican-3 as a Novel Tumor Marker for Melanoma. <i>Clinical Cancer Research</i> , 2004, 10, 6612-6621.	3.2	171
95	Mouse Homologue of a Novel Human Oncofetal Antigen, Glypican-3, Evokes T-Cell Mediated Tumor Rejection without Autoimmune Reactions in Mice. <i>Clinical Cancer Research</i> , 2004, 10, 8630-8640.	3.2	87
96	Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. <i>Biochemical and Biophysical Research Communications</i> , 2003, 306, 16-25.	1.0	385
97	Heat shock protein 105 is overexpressed in a variety of human tumors. <i>Oncology Reports</i> , 2003, 10, 1777-82.	1.2	53
98	Gene Cloning of Immunogenic Antigens Overexpressed in Pancreatic Cancer. <i>Biochemical and Biophysical Research Communications</i> , 2001, 281, 936-944.	1.0	82